This past November The Department of Transportation published a final rule in the Federal Register. The rule amended the DOT’s drug testing program regulation by adding four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). It also added methylenedioxyamphetamine (MDA) as an initial test analyte and removed the testing for methylenedioxyethylamphetaime (MDEA). This rule will be effective January 1, 2018.
You can read the final rule here.
Below is a quick recap of the final rule:
– Effective 1/1/2018 the DOT drug testing panel will include marijuana, cocaine, amphetamines, phencyclidine (PCP), and opiates as well as four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone)
– The shy bladder process has been modified, which requires any specimen that is not sufficient to be discarded by the end of the three hour wait period.
– Laboratories will need to modify reports that are provided to employers and the DOT.
– For Medical Review Officers, the term ‘prescription’ has been clarified.
– For Medical Review Officers, the timing has been modified for communication of a significant safety risk.